GLP1R and metabolic dysfunction-associated steatotic liver disease: Additionally, glucagon-like peptide-1 (GLP-1) receptor agonists, known for their greater impact on weight loss compared with other antihyperglycemic agents, have been reported to reduce hepatic fat content and circulating fetuin-A concentrations in patients with type 2 diabetes mellitus and NAFLD [46].